Inhibrx Rises 4.28% as Technical Signals Stay in Conflict

Market Snapshot

Inhibrx (INBX.O) is currently in a technically neutral phase with mixed signals, posting a 4.28% price rise in recent sessions. While there are positive technical indicators like the MACD Golden Cross, conflicting signals from bearish and bullish patterns suggest investors should closely monitor developments.

News Highlights

1. Faraday Future's EAI Education Push – While not directly tied to Inhibrx, Faraday Future’s plans to establish a scaled education system using robotics tech highlight the growing momentum in tech innovation. Investors may draw parallels in sectors where innovation is key.

2. US Tariffs on Patented Drugs – Proposed tariffs could create ripple effects in the biotech and CDMO (Contract Development and Manufacturing Organization) sectors. Though Inhibrx does not appear to be a major CDMO player, the sector-wide uncertainty could dampen investor sentiment.

3. OPEC+ Output Hike – The oil alliance’s decision to boost output in May could further strain global markets, potentially impacting investor risk appetite. A more cautious approach to stock speculation may follow.

Analyst Views & Fundamentals

JMP Securities analyst Reni J. Benjamin has labeled Inhibrx as "Neutral," with a historically poor performance record (0.0% win rate). The stock currently has a simple average rating of 3.00 and a performance-weighted average of 0.00, both pointing to a pessimistic outlook. Despite a recent 4.28% price increase, these ratings suggest a mismatch between market expectations and price trends.

On the fundamental side, Inhibrx's internal diagnostic score stands at 5.17 (out of 10), indicating moderate weakness. Key fundamentals include:

• Revenue-MV: -18.18% (score: 2.00) – Weakness in revenue relative to market value.
• Net cash flow from operating activities per share (YoY growth rate): 33.70% (score: 3.00) – Positive cash flow growth.
• Total operating revenue (YoY growth rate): 550.00% (score: 3.00) – Strong top-line growth.
• Inventory turnover ratio: 98.02 (score: 3.00) – High turnover is a positive sign of efficient operations.
• Gross profit margin: 100.00% (score: 1.00) – Suggests lack of margin improvement or pressure.
• Net income-Revenue: -4.87% (score: 2.00) – A negative margin ratio signals inefficiency.
• Current assets turnover ratio: 0.89% (score: 2.00) – Indicates limited efficiency in asset usage.
• Cost of sales ratio: 71.87% (score: 3.00) – High cost pressures.
• Asset-MV: -48.64% (score: 2.00) – Assets are undervalued relative to the market.
• Cash-MV: 1.03% (score: 2.00) – Low cash balance relative to market cap.

Money-Flow Trends

Despite the internal diagnostic score of 7.69 (good), the fund-flow data shows a split in momentum. While small and extra-large money flows are positive (inflow ratios of 52.04% and 65.04%, respectively), the large and medium flows are pulling back (49.71% and 49.71% inflow). Overall, big-money and block flows remain positive, with an overall inflow ratio of 55.88%.

Key Technical Signals

Technically, Inhibrx is in a state of neutrality with an overall internal diagnostic score of 6.11. The MACD Golden Cross has a strong bullish internal diagnostic score of 7.8, indicating a potential upward trend. However, this is counterbalanced by the Marubozu White, which carries a score of 3.98 and signals caution. The Long Upper Shadow indicator (score: 6.56) supports a neutral-to-bullish bias but adds to the mixed message.

Recent chart patterns over the last 5 days show the MACD Golden Cross and Long Upper Shadow emerging on April 1, followed by the Marubozu White on March 31 and March 30. This fluctuation in signals underscores the volatility and uncertainty in the short-term trend.

The technical insights confirm a volatile market with no clear direction—long and short signals are relatively balanced, and close attention to price action is recommended.

Conclusion

Inhibrx is showing a mixed bag of signals—strong technical bullishness from the MACD Golden Cross is countered by conflicting bearish and neutral indicators. With a moderate internal diagnostic score of 6.11 and a 4.28% price rise, the stock remains volatile. Given the uncertainty, investors may want to consider waiting for a clearer breakout or a pull-back before entering new positions.